Content Type: Article

  • FATCA/CRS: New HMRC Registration Requirement for UK Investment Managers

    FATCA/CRS: New HMRC Registration Requirement for UK Investment Managers

    ARTICLE / CLIENT ALERT

    FATCA/CRS: New HMRC Registration Requirement for UK Investment Managers

    August 5, 2025

    Read time: 3 min

    Key takeaways
    Overview

    The International Tax Compliance (Amendment) Regulations 2025 impose a new requirement on all entities that are reporting financial institutions for purposes of the UK’s automatic exchange of tax information (AEOI) regime – which includes UK investment managers – to register with HMRC by 31 Dec. 2025.

    Prior to the introduction of this new HMRC registration requirement, UK investment managers were generally not subject to any reporting obligations under the AEOI regime. This was on the basis that UK investment managers, whilst reporting financial institutions, were usually treated as reporting financial institutions that did not maintain any “financial accounts”, and thus had no information to report on an annual AEOI return (HMRC not generally requiring “nil returns”).

    Whilst this should remain the case, so that UK investment managers will continue not to be required to submit annual AEOI returns to HMRC, UK investment managers will be subject to the new, one-time, HMRC registration requirement, on the basis that they are (technically) reporting financial institutions.

    UK investment managers should therefore ensure that they register with HMRC as a reporting financial institution by 31 Dec. 2025.


    This material is for general information purposes only and should not be construed as legal advice or any other advice on any specific facts or circumstances. No one should act or refrain from acting based upon any information herein without seeking professional legal advice. McDermott Will & Schulte LLP* (McDermott) makes no warranties, representations, or claims of any kind concerning the content herein. McDermott and the contributing presenters or authors expressly disclaim all liability to any person in respect of the consequences of anything done or not done in reliance upon the use of contents included herein.

    *For a complete list of McDermott entities visit mwe.com/legalnotices.

    ©2025 McDermott Will & Schulte LLP. All rights reserved. Any use of these materials including reproduction, modification, distribution or republication, without the prior written consent of McDermott is strictly prohibited. This may be considered attorney advertising. Prior results do not guarantee a similar outcome.

    In depth
    Authors
    More insights

  • DOJ-HHS False Claims Act Working Group will pursue healthcare, life sciences enforcement priorities

    DOJ-HHS False Claims Act Working Group will pursue healthcare, life sciences enforcement priorities

    ARTICLE / CLIENT ALERT

    DOJ-HHS False Claims Act Working Group will pursue healthcare, life sciences enforcement priorities

    July 31, 2025

    Read time: 9 min

    Key takeaways
    Overview

    The US Department of Justice (DOJ) and the US Department of Health and Human Services (HHS) recently announced the relaunch of the DOJ-HHS False Claims Act Working Group, intended to “strengthen[] [the agencies’] ongoing collaboration to advance priority enforcement areas.” The working group includes the following entities:

    • HHS Office of General Counsel
    • Centers for Medicare & Medicaid Services (CMS) Center for Program Integrity
    • Office of Counsel to the HHS Office of Inspector General (HHS-OIG)
    • DOJ’s Civil Division, with designees representing US attorneys’ offices
    In depth

    HHS General Counsel, Chief Counsel to HHS-OIG, and the Deputy Assistant Attorney General of the DOJ Commercial Litigation Branch will lead the working group. The group will meet monthly and “maximize cross-agency collaboration,” with HHS facilitating enforcement priority referrals of potential False Claims Act (FCA) violations to the DOJ.

    At the American Health Law Association (AHLA) Annual Meeting, Deputy Assistant Attorney General for the Commercial Litigation Branch of the Civil Division Brenna Jenny stated that part of the working group’s mission will be streamlining investigations, including assessing early whether novel legal theories are viable and supported by leadership.

    The working group announcement details many healthcare-related enforcement priority areas, supplementing a June 2025 memorandum from the DOJ Assistant Attorney General of DOJ’s Civil Division outlining the division’s enforcement priorities. Some priorities, such as the Anti-Kickback Statute (AKS) and Medicare Advantage, have long been areas of significant FCA activity. Predictably, the enforcement priorities have an outsized impact on healthcare and life sciences organizations. These organizations should prepare for continued scrutiny and an increase in qui tam and DOJ-initiated actions advancing both conventional (e.g., Medicare Advantage and AKS) and potentially novel (e.g., barriers to patient access and gender-affirming care) theories.

    Enforcement priorities

    The DOJ articulated its enforcement priorities in a June 11, 2025, enforcement memorandum and the July 2, 2025, working group announcement:

    • The Medicare Advantage industry, including plans and vendors, has experienced FCA investigations concerning risk adjustment data and marketing practices, which likely will continue. The working group mentioned a new priority area related to Medicare Advantage organizations: “barriers to patient access to care, including violations of network adequacy requirements.” CMS also recently announced an aggressive new strategy related to Medicare Advantage audits. CMS will audit all eligible Medicare Advantage contracts for each year and will use additional resources to finish all audits for 2018 – 2024 by early 2026. CMS will work with HHS-OIG to recover overpayments found during these audits. Companies involved with Medicare Advantage, either as a plan, provider, or vendor, can expect increasing government scrutiny and investigative and audit activity.
    • Another priority relates to US President Donald Trump’s political positions set out in Executive Order (EO) 14,168, “Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government,” 90 Fed. Reg. 8615 (Jan. 30, 2025), and EO 14,187, “Protecting Children from Chemical and Surgical Mutilation,” 90 Fed. Reg. 8771 (Feb. 3, 2025). The DOJ stated it will prioritize investigations of providers, hospitals, pharmaceutical companies, and other entities for possible violations of the Food, Drug, and Cosmetic Act, which could lead to FCA exposure, and will pursue claims under the FCA related to billing for what it considers to be impermissible services, such as knowingly submitting claims with incorrect diagnosis codes to evade bans on certain medical treatments. The DOJ has already been active in this space, issuing more than 20 subpoenas to doctors and clinics related to gender-affirming medical procedures performed on minors. Other participants in the healthcare and life sciences sectors may receive subpoenas related to such care.
    • The AKS is prominently featured in the working group’s priority list, which specifically mentions kickbacks related to drugs, medical devices, durable medical equipment, and other products, as well as discounts, rebates, and service fees. At the AHLA Annual Meeting, Jenny mentioned examining the pricing practices of group purchasing organizations, wholesalers, and physician practices, and investigating medical device manufacturer’s financial relationships with large physician practices.
    • Other priorities likely to impact the life sciences and healthcare sectors include drug, device, or biologics formulary placement and price reporting; claims concerning materially defective medical devices impacting patient safety; and alleged manipulation of electronic health record (EHR) systems to promote inappropriate use of Medicare-covered products and services.
    • The DOJ articulated other priorities that, although not specific to the healthcare and life sciences sectors, will still have an impact on those organizations:
      • Citing to President Trump’s January 2025 EO regarding diversity, equity, and inclusion (DEI) and “restoring” purported “merit-based opportunity,” the DOJ’s June 2025 memorandum states that the Civil Division will pursue litigation aimed at combatting allegedly discriminatory practices. The memorandum specifically references FCA cases against entities that receive federal funds but knowingly violate civil rights law. This priority appeared earlier in the National Institutes of Health (NIH) Notice NOT-OD-25-090, released in April 2025 but rescinded in June 2025. The notice announced a new term and condition for all NIH grants, other transaction awards, and cooperative agreements related to eliminating DEI programs and following “all applicable Federal anti-discrimination laws material to the government’s payment decisions for purposes of 31 U.S.C. § 3729(b)(4).” While the notice was rescinded, organizations should watch for similar terms in agreements with or grants from the government and expect the DOJ (and whistleblowers) to strictly enforce them. Organizations should also internally review their hiring practices and any DEI programming to assess potential enforcement or investigation risk based on the administration’s new interpretations and priorities.
      • The DOJ will prioritize investigations and enforcement actions where entities claim federal funds but “knowingly violate federal civil rights laws by participating in or allowing antisemitism.” Organizations should be aware of actions the DOJ could perceive as encouraging antisemitism or failing to protect Jewish employees or clients, which the DOJ has identified as potentially leading to FCA liability.
      • The DOJ’s priorities include increased immigration enforcement as well as “denaturalization” or revoking a person’s US citizenship. The June 2025 memorandum lists various circumstances in which the DOJ would consider a denaturalization proceeding, including cases against individuals who engaged in various forms of financial fraud against the United States, such as Paycheck Protection Program loan fraud and Medicaid/Medicare fraud. Cases also can be referred by a US Attorney’s Office or in connection with pending criminal charges if those charges do not fit within one of the other priorities, or in any other case referred to the Civil Division that the division determines to be sufficiently important to pursue.

    Other working group activities

    The DOJ-HHS working group announcement emphasizes efforts to develop affirmative FCA actions rather than relying on relators to bring claims. The announcement states that the working group “shall maximize cross-agency collaboration to expedite ongoing investigations in these priority areas and identify new leads, including by leveraging HHS resources through enhanced data mining and assessment of HHS and HHS-OIG report findings.”

    The working group will also discuss considerations bearing on whether HHS should implement a payment suspension pursuant to 42 C.F.R. § 405.370 et seq. or whether the DOJ should move to dismiss a qui tam complaint under 31 U.S.C.§3730(c)(2)(A), consistent with Justice Manual Section 4-4.111. This suggests that the DOJ may be putting more priority on, and possibly increasing its frequency in requesting, payment suspensions.

    In the context of FCA investigations or cases, payment suspensions can occur when “a credible allegation of fraud exists against a provider or supplier.” 42 C.F.R. § 405.371(a)(2). These regulations provide very little ability for providers and suppliers to contest payment suspensions, which can have a catastrophic effect, particularly when the government imposes them based on incomplete or inaccurate information early in an investigation. We have seen a notable increase in payment suspensions imposed in 2025 compared to prior years. The working group announcement suggests that this trend may continue.

    One potential bright spot for organizations facing the burden of defending FCA cases after the DOJ declines to intervene is that the working group announcement suggests the DOJ may be more interested in affirmatively dismissing qui tam complaints after declination. A 2018 memorandum from Michael Granston, then-Director of the Commercial Litigation Branch, Fraud Section, articulated seven factors that the DOJ would consider in affirmatively moving to dismiss a relator’s complaint. The DOJ also has pursued affirmative dismissals in a small number of cases. At the AHLA conference, Jenny described evaluating whether to dismiss unmeritorious cases as something she is “passionate about.” Considering when and how to request that the DOJ affirmatively dismiss a declined case will be an important part of an overall FCA defense strategy.

    Key takeaways

    The working group announcement indicates a continued and potentially increased emphasis on FCA enforcement involving healthcare and life sciences organizations. This activity includes enforcement in traditional areas of focus, such as Medicare Advantage and the AKS, but also new priorities such as drug pricing and artificial intelligence use in EHRs. Some of the DOJ’s priorities are more political in nature, including the focus on DEI programs and gender-based care. We expect to see an increase in government action surrounding these priority areas.

    The government’s increased use of payment suspensions merits special focus, given the risk for healthcare organizations. Providers facing an investigation should carefully evaluate the risk and likelihood of a payment suspension and seek advice from counsel experienced in addressing payment suspension risk and, when necessary, challenging it in court.

    Lastly, organizations involved in an FCA action that has been declined should consider ways to appeal to the DOJ to affirmatively dismiss the case.

    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    Dana M. McSherry

    Partner

    Boston

    Matthew L. Knowles

    Partner

    Boston

    Max Doherty

    Associate

    Boston

    More insights

  • REMINDER: Enroll in EDGAR Next by September 12th

    REMINDER: Enroll in EDGAR Next by September 12th

    ARTICLE / CLIENT ALERT

    REMINDER: Enroll in EDGAR Next by September 12th

    August 4, 2025

    Read time: 3 min

    Key takeaways
    Overview

    As a reminder, in 2024, the SEC adopted amendments to the rules and forms related to its EDGAR filing system that will impact the way all filers access and manage their EDGAR accounts and make electronic filings with the SEC. In order to avoid interruption in the ability to make filings, existing filers will need to enroll in EDGAR Next no later than Sep. 12, 2025.

    Please refer to our client Alert for instructions on how to enroll.

    Additional Resources

    The SEC has published additional materials relating to EDGAR Next and enrollment on the below websites:

    Authored by Adriana Schwartz, Brandon S. Gold, Arelys Reyes and Joseph Valerio.

    If you would like to discuss EDGAR Next or have any questions, we encourage you to contact one of the authors of this Alert or your attorney at McDermott Will and Schulte.


    This material is for general information purposes only and should not be construed as legal advice or any other advice on any specific facts or circumstances. No one should act or refrain from acting based upon any information herein without seeking professional legal advice. McDermott Will & Schulte LLP* (McDermott) makes no warranties, representations, or claims of any kind concerning the content herein. McDermott and the contributing presenters or authors expressly disclaim all liability to any person in respect of the consequences of anything done or not done in reliance upon the use of contents included herein.

    *For a complete list of McDermott entities visit mwe.com/legalnotices.

    ©2025 McDermott Will & Schulte LLP. All rights reserved. Any use of these materials including reproduction, modification, distribution or republication, without the prior written consent of McDermott is strictly prohibited. This may be considered attorney advertising. Prior results do not guarantee a similar outcome.

    In depth
    Authors

    Brandon S. Gold

    Partner

    New York – 919 Third Avenue

    More insights

  • A need for speed: FDA piloting voucher program to expedite drug review

    A need for speed: FDA piloting voucher program to expedite drug review

    ARTICLE / CLIENT ALERT

    A need for speed: FDA piloting voucher program to expedite drug review

    July 28, 2025

    Read time: 7 min

    Key takeaways
    Overview

    On July 22, 2025, the US Food and Drug Administration (FDA) started accepting applications to participate in the Commissioner’s National Priority Voucher (CNPV) pilot. This one-year initiative – announced on June 17 – aims to significantly expedite the drug review process from the current timeline of approximately 10 to 12 months to as little as one to two months for a limited number of drugs and biologics that “align with U.S. national interests.” Voucher recipients will benefit from expanded opportunities for direct engagement with FDA subject matter experts. The CNPV pilot intends to lay the groundwork for a new and distinct fast-track review process for select pharmaceutical and biologic innovators. While the launch heralds significant opportunities for the industry, important questions remain regarding eligibility, implementation, and the potential legal and regulatory implications, which we outline below.

    In depth

    Background

    Since joining the FDA in April, Commissioner Marty Makary, MD, MPH, has emphasized the need for more agile, responsive review models, even suggesting that the agency could adopt what he described as “rapid or instant reviews” modeled on the accelerated review processes proven for COVID-19 vaccines under Operation Warp Speed. The CNPV is part of the FDA’s broader strategy to modernize regulatory frameworks and improve the efficiency of drug approval processes. The pilot introduces a team-based approach to reviewing drug and biologics applications. Unlike the standard review process (where applications are passed between multiple FDA offices over several months) the CNPV will bring together a multidisciplinary team of FDA experts to conduct a comprehensive review across a single day. Commissioner Makary compared the CNPV model to “tumor boards,” the fast-paced collaborative sessions between arrays of healthcare specialists that he and other oncologists rely on when determining vital treatment plans for patients.

    Key features of the CNPV program

    The FDA’s FAQ document describes the CNPV pilot as distinct from existing expedited review pathways and the Priority Review Voucher system. While the CNPV incorporates elements of Fast Track Designation, Breakthrough Therapy Designation, Accelerated Approval, and Priority Review Designation, it does not replace them. Unlike these programs, the CNPV pilot will offer a unique one- to two-month timeline for review, excludes devices and combination drug-device applications from eligibility, and prohibits the sale of pilot vouchers. Although CNPVs are nontransferable, they remain valid through changes in company ownership. The CNPV pilot also introduces a novel feature: Companies may receive either a directed voucher tied to a specific investigational new drug or an undesignated voucher not linked to any particular product, which may be used at the company’s discretion before its expiration within two years. While undesignated vouchers may offer companies greater flexibility in leveraging program benefits, the FDA has yet to provide details regarding administration.

    Commissioner Makary stated that the CNPV program is designed to accelerate review of critical drug applications that address urgent public health needs or strengthen the nation’s biomedical infrastructure. The FDA will award a limited number of vouchers to companies developing products that serve key US national priorities. To qualify for a voucher, a sponsor’s product or operations must support at least one of the priority areas listed below, each of which is accompanied by pertinent FDA guidance:

    • Addressing a US public health crisis. One example could include developing a universal vaccine that could provide broad protection against multiple strains of influenza, including those with pandemic potential.
    • Delivering more innovative cures for the American people. The focus for this priority is transformative impact that far outstrips the threshold for breakthrough therapy designation. Examples could include creating a novel immunotherapy that reprograms the body’s immune system to fight multiple diseases or transforming mental health care through a novel treatment for post-traumatic stress disorder.
    • Addressing a large unmet medical need. This includes a condition that available therapies do not adequately diagnose or treat, including drugs to treat or prevent rare diseases or addressing the United States’ chronic disease crisis.
    • Onshoring drug development and manufacturing to advance the health interests of Americans and strengthen US supply chain resiliency. Examples could include companies with new manufacturing establishments that shift manufacturing of essential medicines (such as generic sterile injectables) from foreign facilities to the US or a clinical trial that maintains robust US enrollment to support generalizability for Americans against the US standard of care.
    • Increasing affordability. One example could include a company that lowers the US price of a drug or drugs consistent with Most Favored Nation pricing or reduces other downstream medical utilization to lower overall healthcare costs.

    Sponsors seeking a CNPV voucher must submit the Chemistry, Manufacturing, and Controls portion of a drug or biologic application and the draft labeling at least 60 days before submitting a final application for approval. The FDA emphasizes that CNPV can be applied to drug products or biologics at any stage of development. The program aims to streamline efficiencies by allowing most of the product marketing application to be submitted before clinical trials conclude. If the voucher is granted during the investigational new drug phase, the company will receive the benefits of the CNPV’s enhanced communication with sponsors. Sponsors are expected to maintain ongoing communication with the FDA throughout the CNPV review process, reflecting the agency’s emphasis on transparency and collaborative engagement. Interim reviews throughout the process will not only ensure prompt responses from the FDA but also provide drug manufacturers with opportunities to respond and correct any issues before the completion of clinical trials. The FDA reserves the right to extend the review window if the application is incomplete or if the trial results are ambiguous.

    Next steps

    By submitting CNPV applications that align with the FDA’s listed priorities, drug and biologic companies may benefit from expedited review processes and expanded, real-time engagement with agency experts. The FDA intends for the year-long pilot to serve as a proof of concept for innovative marketing review models and broader industry interaction frameworks that could inform a future fast-track pathway. Many questions remain, such as how the agency will apply selection criteria, the transparency of the process, and whether there will be a mechanism to review unfavorable decisions, among others. Although the FDA has pledged to issue further guidance, basic details such as the estimated number of vouchers expected through the pilot remain undisclosed. Without clear, published standards, sponsors may struggle to assess whether their product or company qualifies as a viable candidate, especially given that final discretion rests with the commissioner. Finally, the CNPV pilot may face familiar concerns tied to accelerated approval models. Some stakeholders have raised safety questions about drugs reviewed on compressed timelines, particularly in light of FDA resource constraints. Nonetheless, the FDA states that safety and efficacy standards will not be compromised under the CNPV.

    McDermott will continue to monitor the rollout of the year-long CNPV pilot, including additional guidance, potential extensions of the initiative, or the establishment of a permanent national priority pathway. For more information on applying for a CNPV or about FDA review processes, please contact a member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Amanda Lee, a summer associate in the Washington, DC, office, also contributed to this article.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Sydney Merritt Martinez

    Associate

    Washington, DC

    More insights

  • Reducing hospital payments: CMS proposes expanded site-neutral payment policy for drug administration services

    Reducing hospital payments: CMS proposes expanded site-neutral payment policy for drug administration services

    ARTICLE / CLIENT ALERT

    Reducing hospital payments: CMS proposes expanded site-neutral payment policy for drug administration services

    July 25, 2025

    Read time: 8 min

    Key takeaways
    Overview

    Consistent with recent attention from Congress and rhetoric from the Trump administration, the Calendar Year 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) proposed rule (the Proposed Rule) includes site-neutral payment proposals and requests for information (RFIs) related to potential future site-neutral payment policies. The Centers for Medicare & Medicaid Services (CMS) has broad statutory authority to implement site-neutral payment policies as to hospital outpatient services, so long as such policies are characterized as being necessary to control the volume of services furnished in such settings. The Proposed Rule was published in the Federal Register on July 17, 2026, and comments are due September 15, 2025.

    In depth

    Background

    Medicare pays for services furnished in a physician’s office based on the Medicare Physician Fee Schedule (MPFS), while Medicare pays for similar services furnished in hospital outpatient departments under the OPPS. When services are furnished in hospital outpatient departments, including provider-based departments (PBDs) of a hospital, Medicare typically makes two payments: (1) a payment to the physician providing professional services in the hospital setting; and (2) a payment to the hospital for the overhead and facility component of the services. In contrast, in a physician office setting, the payment to the physician includes both the professional component and the overhead associated with the services. The payment differential reflects the typically higher cost of furnishing care in hospital-based settings.

    This payment methodology usually means that if a Medicare patient receives similar services in a physician office and hospital outpatient department, Medicare pays more for the service provided in a hospital setting. CMS has estimated that, on average, hospitals are paid 60% more than physician offices for similar services. Medicare patients can also face higher costs when receiving services in a hospital outpatient department because the patient pays 20% coinsurance on the Medicare OPPS rate.

    Policymakers and patient advocates have long expressed concerns that these differences in payment are not justified and create incentives for hospitals to acquire physician practices to capture higher payments. In recent years, there has been increasing criticism that these incentives have led to widespread vertical integration and increased Medicare expenditures, as well as harm to beneficiaries who face higher out-of-pocket costs. Site-neutral payment policies have been promoted as a way to eliminate incentives to perform services in hospital outpatient departments that could be furnished in lower-cost settings, such as physician offices, often with little attention to the actual reasons that certain services or patients are better suited for one site of service over another.

    In an effort to address these concerns, in 2017, Congress required CMS to implement a site-neutral payment policy for many off-campus hospital outpatient departments. Under the Bipartisan Budget Act of 2015 (BiBA), as amended by the 21st Century Cures Act, items and services furnished at certain off-campus PBDs are no longer considered “covered outpatient services” that are paid under the OPPS. Those items and services furnished are now paid under a payment rate that approximates the MPFS rate. On-campus PBDs and off-campus PBDs that were furnishing services prior to November 2, 2015, together with certain other PBDs, are considered to be “Excepted Off-Campus PBDs .” This was followed in 2019 by a CMS-initiated site-neutral payment policy for office visits furnished at all off-campus hospital outpatient departments, justified as necessary to control increases in the volume of such services.

    In late 2024, a report from the Congressional Budget Office, titled “Options for Reducing the Deficit: 2025 to 2034,” included three site-neutral payment policies as options for reducing mandatory spending. Namely, Congress could pay site-neutral rates for most Medicare services provided in off-campus and on-campus hospital outpatient departments or apply site-neutral rates to either drug administration services or imaging services for all off-campus hospital outpatient departments.

    Congress has recently considered implementing several statutory site-neutral payment policies. Most recently, in the bipartisan December 16, 2024 continuing resolution to fund the federal government that nearly passed Congress  to fund the federal government, a statutory provision was included that would have required a separate billing identification number for off-campus hospital outpatient departments and would have required hospitals to submit provider-based attestations for all off-campus hospital outpatient departments. These provisions would have provided CMS with greater visibility and oversight regarding services furnished by off-campus hospital outpatient departments. This provision was not ultimately enacted in the continuing resolution adopted by Congress to fund the government through March 14, 2025 (or in subsequent government funding legislation).

    More recently, and specific to payment differences related to drug administration, on April 15, 2025, President Trump issued Executive Order 14273, titled “Lowering Drug Prices by Once Again Putting Americans First,” which directed the Secretary of Health and Human Services to propose regulations to ensure that Medicare payment does not encourage the administration of drugs by hospital outpatient departments as opposed to physician office settings.

    Proposed expansion of site-neutral payments to drug administration services

    Consistent with Executive Order 14273, in the Proposed Rule, CMS proposed to use its authority under 42 U.S.C. § 1395l(t)(2)(F) to expand its existing site-neutral payment policies to include drug administration services furnished at all off-campus PBDs. Under this statutory authorization, CMS has the authority to “develop a method for controlling unnecessary increases in the volume of covered” outpatient services. Specifically, CMS is proposing to apply the MPFS payment rate for any Healthcare Common Procedure Coding System (HCPCS) codes covering drug administration ambulatory payment classifications when provided at Excepted Off-Campus PBDs, rather than an OPPS rate. Off-campus PBDs that are not excepted are already subject to a MPFS-equivalent payment rate for these services. CMS is also proposing to exclude rural sole community hospitals from the proposed site-neutral policy for drug administration services.

    As the impetus for this change, CMS cited a substantial shift over time from drug administration in physician offices to administration in PBDs. As a result, the agency expressed concerns about higher costs for both beneficiaries who receive drugs administered in PBDs and the Medicare trust fund due to higher reimbursement for those services under the OPPS.

    CMS reasons that providing services in a PBD at a higher cost is unnecessary if a patient can safely receive those services in a physician office for a lower cost. To support this finding, the agency cited a study which found that 68% of drug administration services currently take place in physician offices, indicating they are safely performed in multiple settings. In other words, because drug administration services are routinely – and safely – performed in physician offices, there is no reason to pay a higher OPPS rate for these services in a PBD setting. Rather, CMS points to the payment incentive as the primary motivator for the shift in care setting for these drug administration services, even though a minority of such services are provided in PBDs.

    Requests for information

    In the Proposed Rule, CMS also included additional RFIs related to site-neutral payment policies. CMS is interested in whether there are other services that should be paid at an MPFS-equivalent rate when furnished at an excepted off-campus PBD, and the agency is particularly interested in imaging without contrast services (APCs 5521-5524). CMS also requested public input on the potential impact of a policy reimbursing clinic visits (HCPCS code G0463) performed in on-campus outpatient departments at the MPFS rate. Finally, CMS requested feedback on how the agency can develop a more systematic process for identifying ambulatory services at risk of shifting to a hospital setting due to financial incentives rather than medical necessity.

    The RFIs send a clear signal to stakeholders that CMS intends to continue its efforts to expand site-neutral payment policies, particularly where the site of care may be driven by financial incentives.

    Analysis

    In the proposed rule, CMS continues to make clear that it will seek to expand the use of site-neutral payment policies in its efforts to control Medicare expenditures.

    However, the focus on financial impact fails to address those reasons that validate the need for differences in payment. While CMS recognizes in the Proposed Rule that hospital PBDs “serve unique patient populations and provide services to medically complex beneficiaries” and concludes that there is no evidence to demonstrate the need for higher payment of services that could be provided in a lower-cost setting, it fails to fully address hospitals’ higher baseline expenses and the need for providing care to patients with complex conditions that make PBD care clinically necessary. Historically, the higher payment rates for services provided in hospitals have been meant to address the higher level of care required by patients in such settings, the higher costs of providing care to patients in hospitals, and the costs of maintaining services required to be provided by hospitals (such as emergency care).

    If hospital PBD reimbursements for critical service lines are reduced to match the MPFS rate, which is approximately 60% lower than the OPPS rate, that will have meaningful ramifications for hospitals’ overall financial health and long-term program viability.

    While major expansions in site-neutral payment policies, such as those that might eliminate or combine entire payment systems, will likely require congressional action, through the Proposed Rule and similar actions, CMS will continue its efforts to reshape reimbursement based on the site of care.

    Stakeholders should consider using the opportunity to provide public comments on the Proposed Rule to highlight the impacts of expanding site-neutral policies on their ability to provide clinically appropriate care and serve their communities, particularly related to drug administration.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Sandra M. DiVarco

    Partner

    Chicago

    Caroline Reignley

    Partner

    Washington, DC

    Margaret Houtz

    Associate

    Boston

    Nathan Gray

    Associate

    Washington, DC

    More insights

  • Bye-bye, bright dyes: Strategies for responding to FDA’s synthetic food dye phase-out

    Bye-bye, bright dyes: Strategies for responding to FDA’s synthetic food dye phase-out

    ARTICLE / CLIENT ALERT

    Bye-bye, bright dyes: Strategies for responding to FDA’s synthetic food dye phase-out

    July 24, 2025

    Read time: 6 min

    Key takeaways
    Overview

    On April 22, 2025, the US Food and Drug Administration (FDA) and the US Department of Health and Human Services (HHS) announced a plan to phase out petroleum-based synthetic dyes from the US food supply by the end of 2026, citing health risks associated with these dyes. Food manufacturers should stay vigilant, as the agency will soon begin revoking authorization for the use of Citrus Red No. 2 and Orange B in food products. This initiative is part of a broader regulatory shift, as evidenced by the FDA’s May 2025 draft guidance recommending similar changes for color additives in approved or marketed drug products.

    In depth

    Plan to phase out synthetic color additives

    Petroleum-based synthetic dyes are synthetic color additives derived from crude oil. The dyes are most commonly used in processed food and beverages such as candy, baking decorations, and sports drinks to make the items appear more vibrant or consistent in color. However, these dyes are also used in some supplements, medications, and even medical devices such as contact lenses or nonabsorbable sutures. The FDA has already banned certain additives, including Red No. 3, which must be removed from food items by 2027 – 2028.

    This move builds on the FDA’s long-standing regulatory framework for color additives, which places strict requirements and restrictions on the use of color additives in food. The FDA requires most color additives in food to be batch-certified and approved for specific uses under the Food, Drug, and Cosmetic Act, and any unapproved uses are prohibited. All ingredients, including color additives, must be listed on labels. Certified ones must be listed by name, but exempt ones may be listed generically.

    Before the recent announcement of the plan to eliminate food dyes from the US food supply, the FDA had only approved eight artificial dyes for human consumption:

    • Red No. 40
    • Blue No. 1
    • Blue No. 2
    • Citrus Red No. 2
    • Green No. 3
    • Orange B
    • Yellow No. 5
    • Yellow No. 6

    As announced on April 22, 2025, the FDA is taking decisive steps to phase out synthetic food dyes, beginning with the revocation of Citrus Red No. 2 and Orange B. This marks the first phase in a broader effort to eliminate six additional dyes, including Red No. 40 and Yellow No. 5, by the end of 2026. The FDA has cited potential health risks and consumer demand for cleaner ingredients. To accelerate the transition, the FDA will fast track approval of natural alternatives, such as butterfly pea flower extract and calcium phosphate, to help manufacturers shift without disruption. The FDA has also called for an early removal of Red No. 3, moving up the original 2027 – 2028 deadline, as concerns over its continued use in food and beverages grow.

    Momentum is building across both the private and public sectors to move away from synthetic food dyes. Several leading food and beverage companies have already announced plans to eliminate artificial dyes from all products within the next two years. At the state level, Texas recently passed a law requiring food manufacturers to place warning labels on food containing any one of 44 dyes and additives banned in other countries starting in 2027. Several of these ingredients, including Blue No. 1, Blue No. 2, and Green No. 3, are also on the FDA’s proposed ban list, signaling a broader national effort to restrict synthetic dyes in the US food supply.

    FDA draft guidance on replacing color additives in drug products

    On May 29, 2025, the FDA announced an expanded effort to reduce synthetic dyes beyond food and beverages, extending its focus to drug products. As part of this initiative, the agency released draft guidance providing recommendations for replacing color additives in approved or marketed drug products. Although this guidance targets pharmaceuticals, it reflects the broader regulatory momentum toward eliminating synthetic dyes across sectors.

    This draft guidance recommends that manufacturers comply with the following requirements:

    • Manufacturers must verify that selected color additive replacements continue to comply with color additive regulations. Color additives not listed have yet to be deemed safe and therefore may not be used.
    • Holders of a new drug application or an abbreviated new drug application must submit changes being effected in 30 days (CBE-30) supplements within 30 days of implementing a color additive replacement. These submissions should include evidence confirming that the replacement does not affect the drug’s effectiveness and that the product continues to meet established quality standards.
    • Records documenting the replacement’s sustained effectiveness and overall drug composition should be maintained at the drug manufacturing facility through the product’s expiry date.

    Like the FDA and HHS’s plan to phase out petroleum-based synthetic dyes, the draft guidance reflects the Trump administration’s broader push to eliminate artificial additives in favor of natural alternatives, signaling that manufacturers across industries should begin preparing for a future with fewer synthetic ingredients. Key action items include the following:

    • Conduct a dye inventory assessment to identify all stock keeping units and formulations containing any of the above-listed FDA-certified synthetic dyes.
    • Engage with the food industry association or your own industry group to make your voice heard and learn about other responses in your industry.
    • Initiate reformulation planning by evaluating natural color alternatives and considering technical feasibility, supply chain availability, and consumer impact. FDA has already approved petitions for new natural blue and white additives, and more are expected in the near term.
    • Ensure that marketing and regulatory teams are prepared to update product labeling to reflect reformulated ingredient lists and comply with FDA disclosure requirements for certified and exempt color additives.
    • Evaluate supply chain and cost impacts. Work with suppliers to confirm transition timelines and ensure secure sourcing of compliant natural colorants.

    Next steps

    The draft guidance for replacing color additives in drug products is open for public comment until July 29, 2025. Companies that manufacture, distribute, or private-label food or drug products containing any of the eight currently approved synthetic dyes should begin compliance planning immediately.

    The McDermott difference

    McDermott will continue to monitor developments to the plan to phase out petroleum-based synthetic dye in food. For more information on complying with the removal of synthetic dyes, please reach out to the authors of this article or any member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Tyler Barton

    Associate

    New York – One Vanderbilt Avenue

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Sydney Merritt Martinez

    Associate

    Washington, DC

    More insights

  • Before it hits the shelf: FDA reprocesses the new dietary ingredient notification process

    Before it hits the shelf: FDA reprocesses the new dietary ingredient notification process

    ARTICLE / CLIENT ALERT

    Before it hits the shelf: FDA reprocesses the new dietary ingredient notification process

    July 24, 2025

    Read time: 5 min

    Key takeaways
    Overview

    On June 11, 2025, the US Food and Drug Administration (FDA) released educational materials to broaden dietary supplement manufacturers’ and distributors’ awareness and understanding of the FDA’s new dietary ingredient notification (NDIN) process. These materials aim to assist the dietary supplement industry in correctly preparing and submitting NDINs for FDA approval and highlight common issues in the NDIN submission process. The FDA uses the notification process as a crucial tool to identify and evaluate the safety of new dietary ingredients (NDIs) in dietary supplements prior to market authorization and customer consumption.

    In depth

    Background

    The FDA’s authority to oversee dietary ingredient notifications is established under Section 413 of the Federal Food, Drug, and Cosmetic Act. Under the act, manufacturers and distributors of an NDI that has not been present in the food supply as an article used for food, or of a dietary supplement that contains the NDI, must submit a premarket safety notification to the FDA at least 75 days before introducing the product to the market. Notifications should generally include information conveying the basis for why the manufacturer or distributor reasonably concludes that the NDI will be considered safe for its recommended use. NDINs should specify the category that the NDI belongs to, describe the physical and chemical composition and structure of the NDI, depict the NDI’s manufacturing process, and include a specification sheet that describes the NDI’s critical identity and safety attributes along with any impurities and contaminants.

    If the required premarket notification is not submitted to the FDA, the dietary supplement is deemed to be adulterated. The FDA will not evaluate incomplete NDINs. Therefore, ensuring complete and accurate NDINs is crucial since they represent the FDA’s only opportunity to assess the safety and identity of NDIs in dietary supplements before they becomes available to consumers.

    The NDIN submission process

    To facilitate an efficient and timely FDA review of NDINs, the agency released two educational videos and a supplemental fact sheet. The materials provide guidance to NDI manufacturers and distributors to ensure that notifications are complete and accurate, and to avoid delays in the review process. These educational materials aim to simplify and increase the transparency of the NDIN process.

    The first video, “Important Aspects of the NDIN Process,” and the fact sheet outline common issues the FDA has observed in the NDIN submission process that may lead to unnecessary delays. These issues can be addressed by ensuring that notifications:

    • Specify the dietary category to which the NDI belongs
    • Cover the broadest possible use of the NDI
    • Include sufficient identity information for the NDI (e.g., physical and chemical composition, manufacturing process, identity and safety attributes) and how scientific evidence supports such information
    • Exclude irrelevant or extraneous information that does not support the notifier’s conclusions about the identity or safety of the NDI
    • Properly reference and provide complete copies of referenced articles or other underlying materials to support the safety of the NDI along with any necessary English translations

    The second video, “Correspondence Between FDA and the Notifier,” provides further clarification on what manufacturers can expect after an NDIN has been submitted to the FDA. The video encourages electronic submission through the Center for Food Safety and Applied Nutrition Online Submission Module ePortal, which guides users through required elements and enables email updates. Paper submissions are also accepted with specific formatting and follow-up requirements.

    Once a notification is received, the FDA issues an acknowledgment letter with the official filing date, triggering a 75-day review period during which the product cannot be marketed. The video explains that FDA reviewers may request additional information, and if a substantive amendment is submitted, the review clock resets. The video also covers the types of response letters manufacturers may receive, including a no objection letter, a letter raising concerns about identity or safety, a letter identifying regulatory deficiencies, or a letter indicating that the ingredient is not a dietary ingredient or is intended for a non-supplement use. NDINs and response letters remain confidential for 90 days post-filing, after which they are posted on regulations.gov, excluding trade secrets or confidential commercial information. Finally, the FDA encourages potential notifiers to request a pre-submission meeting to help ensure their NDINs are complete and compliant.

    Next steps

    Recent developments in FDA regulations resulting from the Trump administration’s Executive Order (EO) 14221, “Making America Healthy Again by Empowering Patients With Clear, Accurate, and Actional Healthcare Pricing Information,” have emphasized transparency within the drug industry and consumer empowerment to make well-informed healthcare decisions. Manufacturers and distributors of dietary supplements should take proactive steps to ensure that their NDIs are safe and effective for consumer use. Companies involved in the dietary supplement industry should conduct a thorough review of their current protocols to ensure that their NDIs are fully compliant with the NDIN process and that they align with the objectives of EO 14221.

    The McDermott difference

    McDermott will continue to monitor any changes to the FDA’s dietary ingredient notification procedures and timeframes. If you have questions about how this notification process could impact your business, please contact the authors of this article or a member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Sydney Merritt Martinez

    Associate

    Washington, DC

    More insights

  • CPPA moves closer to finalizing amended CCPA regulations

    CPPA moves closer to finalizing amended CCPA regulations

    ARTICLE / CLIENT ALERT

    CPPA moves closer to finalizing amended CCPA regulations

    July 24, 2025

    Read time: 3 min

    Key takeaways
    Overview

    As the California Privacy Protection Agency (CPPA) prepares for its July 24, 2025, meeting, it released a revised set of California Consumer Privacy Act (CCPA) regulations that contain modest changes to the ones it released in May. The latest version contains substantive changes in two key areas: 1) the content and structure of the cybersecurity audit report and 2) the processing scenarios that are considered “high risk” and trigger a risk assessment, both of which are described in greater detail below.

    The fact that only modest changes were made following the latest round of public comment demonstrates that the CPPA is positioning these proposed regulations to move to their final stage before the end of year. That means that companies should, if they have not already, begin to prepare for compliance with the new regulations as early as Q4 2025. As described in our prior client alerts (Draft CCPA regulations stalled as agency struggles with applicability of ADMT rules and CPPA releases proposed updates to CCPA regulations and unveils new draft privacy assessment and ADM rules), the new regulations include a variety of changes to which companies will have to adapt.

    In depth

    Content and structure of the cybersecurity audit report

    In the latest draft regulations, the CPPA clarified that audit reports should contain information on three key areas:

    1. The policies, procedures, and practices that the audit assessed;
    2. The criteria used for the audit; and
    3. The specific evidence examined, such as documents reviewed, sampling/testing performed, and interviews conducted.

    Time is of the essence to conduct a gap assessment and prepare for these new regulations.

    Changes in the processing scenarios that are considered “high risk”

    With respect to high-risk processing activities that require risk assessments, the latest draft regulations replaced the “Profiling” defined term with the list of activities that constitute “Profiling” in the section of the regulations that trigger risk assessments. These changes are not substantive, but in their explanation for the change, the CPPA explained it thought the edit would help clarify what type of automated decisionmaking processing was high risk.

    The draft regulations also add a narrow exception to risk assessments where a “consumer’s personal information solely to deliver goods to, or provide transportation for, that consumer at a sensitive location.”

    What’s next?

    The CPPA staff have prepared the package of revised materials to be filed with the Office of Administrative Law, which is the final step before the regulations can be finalized. The staff and board are still targeting November 2025 to finalize this rulemaking. Thus, time is of the essence to conduct a gap assessment and prepare for these new regulations.

    If you are interested in building out your CCPA compliance program, please contact your regular McDermott lawyer or one of the authors.

    Authors

    David P. Saunders

    Partner

    Chicago

    Amy C. Pimentel

    Partner

    Boston

    More insights

  • Paid Prenatal Leave in New York City: A New Layer of Compliance for Employers

    Paid Prenatal Leave in New York City: A New Layer of Compliance for Employers

    ARTICLE / CLIENT ALERT

    Paid Prenatal Leave in New York City: A New Layer of Compliance for Employers

    July 22, 2025

    Read time: 3 min

    Key takeaways
    Overview

    To align with New York State’s paid prenatal leave requirements, which we discussed here, the New York City Department of Consumer and Worker Protection (“DCWP”) has amended its rules for New York City’s Earned Safe and Sick Time Act (“ESSTA”). The amended rules, which can be found here, took effect on July 2, 2025 (“Rules”). The Rules do not establish a separate leave entitlement, but instead “incorporate by reference” the State law which went into effect on Jan. 1, 2025 and requires that employers provide employees twenty (20) hours of paid prenatal leave per 52-week period.

    Although the leave entitlement for employees remains the same, the Rules add additional obligations for New York City employers. Employers must maintain a written paid prenatal leave policy that complies with the Rules and are required to distribute the policy to employees at the time of hire, within 14 days of the effective date of any changes to the policy, and upon request. 

    The Rules also introduce a disclosure requirement, consistent with existing requirements for paid sick and safe time reporting under ESSTA. For each pay period in which an employee uses paid prenatal leave, the employer must inform the employee, either on their paystub or electronically, of the number of hours of paid prenatal leave used and the total balance remaining for the 52-week period.

    New York City employers must also post and provide employees with an updated Notice of Employee Rights that includes information about paid prenatal leave entitlements. This notice must be distributed to both new hires and current employees, posted in a conspicuous location in the workplace, and accompanied by an acknowledgement of receipt from employees, which employers are required to retain.

    New York City employers should review and update their existing policies to ensure compliance with these requirements. DCWP has authority to promulgate and enforce rules implementing local laws, including ESSTA. When DCWP issues amended rules, employers must comply or face potential enforcement actions. For any violations of the paid prenatal leave requirements, employers may be subject to civil penalties, including fines (including up to $10,000 for retaliation), restitution orders, interest, liquidated damages and/or attorneys’ fees.

    Authored by Mark Brossman, Max Garfield, Donna Lazarus, Ronald Richman, Martin Schmelkin, Scott Gold and Michelle Orge.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Max Garfield

    Partner

    New York – 919 Third Avenue

    Donna K. Lazarus

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Martin L. Schmelkin

    Partner

    New York – 919 Third Avenue

    Michelle M. Orge

    Associate

    New York – 919 Third Avenue

    More insights

  • FinCEN Postpones Effective Date of AML/CFT Program Rule for Investment Advisers to 2028

    FinCEN Postpones Effective Date of AML/CFT Program Rule for Investment Advisers to 2028

    ARTICLE / CLIENT ALERT

    FinCEN Postpones Effective Date of AML/CFT Program Rule for Investment Advisers to 2028

    July 21, 2025

    Read time: 3 min

    Key takeaways
    Overview

    On July 21, 2025, the US Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) announced its intention to postpone[1]the effective date of the rule extending the anti-money laundering/countering the financing of terrorism program and related requirements to SEC-registered investment advisers and exempt reporting advisers (“IA AML/CFT Rule”).[2]FinCEN anticipates delaying the effective date of the IA AML/CFT Rule from Jan. 1, 2026, to Jan. 1, 2028, subject to working through the rulemaking process to effect such delay.

    In its announcement, FinCEN recognized that postponing the effective date of the IA AML/CFT Rule may help ease compliance costs for the industry and reduce regulatory uncertainty. During the postponement, FinCEN intends to revisit the substance and scope of the IA AML/CFT Rule through a future rulemaking process. The announcement does not indicate whether or how the IA AML/CFT Rule requirements, including information sharing, special due diligence and recordkeeping, may change.  

    FinCEN also stated that it will work with the SEC to revisit the joint proposed rule establishing customer identification program requirements for registered investment advisers and exempt reporting advisers.[3]

    We will continue to monitor for further updates from FinCEN, including future rulemakings. 

    Authored by Melissa G.R. Goldstein, Betty Santangelo, Hannah Thibideau and Kyle B. Hendrix.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] US Department of the Treasury, “Treasury Announces Postponement and Reopening of Investment Adviser Rule” (July 21, 2025).

    [2] Final Rule, Anti-Money Laundering/Countering the Financing of Terrorism Program and Suspicious Activity Report Filing Requirements for Registered Investment Advisers and Exempt Reporting Advisers, 89 Fed. Reg. 72156 (Sept. 4, 2024).

    [3] Joint Notice of Proposed Rulemaking, Customer Identification Programs for Registered Investment Advisers and Exempt Reporting Advisers, 89 Fed. Reg. 44571 (May 21, 2024).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    More insights